Targeted delivery of doxorubicin into tumor cells to decrease the in vivo toxicity of glutathione-sensitive prodrug-poloxamer188-b-polycaprolactone nanoparticles and improve their anti-tumor activities.

Shi, Yongli; Hou, Xueyan; Yu, ShaSha; Pan, Xiaofei; Yang, Mingbo; Hu, Jie; Wang, Xiao

Shi, Yongli; Hou, Xueyan; Yu, ShaSha; Pan, Xiaofei; Yang, Mingbo; Hu, Jie; Wang, Xiao.

Afiliação

Shi Y; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China. Electronic address: shiyongli2005@163.com.
Hou X; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
Yu S; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
Pan X; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
Yang M; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
Hu J; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
Wang X; College of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.

Colloids Surf B Biointerfaces ; 220: 112874, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36201863

Assuntos

Nanopartículas; Neoplasias; Pró-Fármacos; Camundongos; Animais; Pró-Fármacos/farmacologia; Doxorrubicina/química; Nanopartículas/química; Neoplasias/tratamento farmacológico; Glutationa; Camundongos Endogâmicos BALB C; Linhagem Celular Tumoral; Sistemas de Liberação de Medicamentos

Palavras-chave

4T1 cells; Anti-tumor; DOX; GSH-responsibility; Nanoparticles; in vivo toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Nanopartículas / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Animals Idioma: En Revista: Colloids Surf B Biointerfaces Assunto da revista: QUIMICA Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google